Your reasoning on SPPI seems to be muddle-headed, at best. I haven't read Justin Hall recently, but I fail to see why an attack on Hall becomes a justified attack on SPPI. The simple fact is that SPPI delivered on Zevalin sales in a way that most investors (including me) thought that they couldn't. If SPPI succeeds in convincing the FDA to eliminate the bioscan requirement, sales of Zevalin may well increase.
I don't know why you brought TEVA into the discussion of SPPI. Maybe it was something in Hall's writings that prompted you to mention TEVA. But if that's the case, you ought to make clear what exactly it is that you are referring to. (Ah, I just researched Hall's recent writings on SPPI, so now I see what got under your skin. Even when I was holding shares of SPPI, I never counted leucovorin sales as part of my evaluation of the company.)
You may not like Raj (Hall seems to me to be irrelevant to a discussion of SPPI's prospects.), but you've got to admit that Raj has certainly produced for shareholders.
News 
Market Data 
Discover 
AI
